Acumen Pharmaceuticals to Announce Q2 Results on August 13, 2024

NEWTON, Mass., Aug. 06, 2024 – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a biopharmaceutical company in the clinical stages of developing a new therapeutic approach targeting toxic soluble amyloid beta oligomers for treating Alzheimer’s disease, announced it will release its second-quarter 2024 financial results on Tuesday, August 13, 2024. Acumen plans to host a conference call and live audio webcast at 8:00 a.m. ET on the same day to present a business and financial update.

Participants interested in joining the live conference call should register ahead of time. Registration will provide the necessary dial-in numbers and PIN. The webcast audio will also be accessible online, with an archived version available for at least 30 days on the company's website, specifically in the Investors section.

Acumen Pharmaceuticals is known for its development of a groundbreaking therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) as a treatment for Alzheimer’s disease. The company's scientific founders have been pioneers in researching AβOs, which a growing body of evidence suggests are early and persistent triggers of Alzheimer's disease pathology. Acumen is actively advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody designed to selectively target these toxic soluble AβOs, in its current Phase 2 clinical trial, ALTITUDE-AD (NCT06335173), which focuses on patients with early symptomatic Alzheimer's disease. This follows the positive results obtained in its Phase 1 trial, INTERCEPT-AD.

Headquartered in Newton, Mass., Acumen Pharmaceuticals remains dedicated to pioneering the treatment of Alzheimer's disease through innovative scientific research and clinical development. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!